Abrégé

The present invention relates to extracellular vesicles derived from regulatory B cells, and the use thereof in therapy.

Classes IPC  ?

• A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
• C12N 5/0781 - Cellules B; Leurs progéniteurs

Abrégé

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• B01D 15/36 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p.ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
• B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétés; Procédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés

Abrégé

The present invention concerns a new urinary metabolomic signature of spontaneous operational tolerance (SOT) in kidney transplant recipients/patients (KTR) showing enrichment in tryptophan-derived metabolites.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a dermatological composition comprising at least one polar extract of an alga of the Skeletonema genus or a photosensitizer derived therefrom, for the treatment of acne or bacterial infections; as well as a process for decontaminating a surface using a polar extract of an alga of the Skeletonema genus or a photosensitizer derived therefrom.

Classes IPC  ?

• A61K 36/02 - Algues
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 8/9706 - Algues
• A61P 17/10 - Antiacnéïques
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

The present invention relates to the use of a formulation comprising a phosphocalcic cement and a physical and/or ovalent hydrogel of polysaccharides for 3D printing, more particularly for bone regeneration and/or bone repair. The present invention also relates to a kit for 3D printing of bone implants comprising a phosphocalcic cement and a physical and/or covalent hydrogel of polysaccharides as well as to a method to prepare a formulation for 3D printing comprising a step of mixing a phosphocalcic cement and a physical and/or covalent liquid hydrogel precursor of polysaccharides.

Classes IPC  ?

• A61L 27/38 - Cellules animales
• A61L 27/20 - Polysaccharides
• A61L 27/52 - Hydrogels ou hydrocolloïdes
• A61L 27/54 - Matériaux biologiquement actifs, p.ex. substances thérapeutiques
• A61L 27/46 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges inorganiques contenant du phosphore

Abrégé

The present invention relates to a method for segmenting a digital image, for example to accurately segment cerebral vasculature on MRI-TOF images of a brain. The method first uses a model that imitates the perception of luminance contrasts by a human observer to accentuate a contrast between structures of interest, such as cerebral vasculature, and the image background. Then, the image is thresholded using an adaptive threshold. This enhanced segmentation method can be used to process digital images before launching further machine-implemented characterizations of the structures of interest, such as detecting and characterizing bifurcations of the cerebral vasculature for intra-cranial aneurysm prediction.

Classes IPC  ?

• G06T 7/136 - Découpage; Détection de bords impliquant un seuillage
• G06T 7/11 - Découpage basé sur les zones
• G06T 5/00 - Amélioration ou restauration d'image

Abrégé

The present invention relates to a method for radioiodination or radioastatination of a biomolecule such as proteins and antibodies by reacting a biomolecule carrying a hetero(aryl) boronic acid group with a radioiodide or astatide salt, in the presence of a catalyst and a ligand, in a buffer solution, in order to obtain a radioiodo- or astatolabeled biomolecule. The method of the invention is thus a single step method easy to be implemented and efficient for both radioiodination and radioastatination of antibodies.

Classes IPC  ?

• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07F 5/02 - Composés du bore

Abrégé

SkeletonemaSkeletonema Skeletonema or a photosensitizer derived therefrom.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 36/03 - Phaeophycota ou phaeophyta (algues brunes), p.ex. Fucus
• A61P 31/04 - Agents antibactériens
• A61P 17/10 - Antiacnéïques

Abrégé

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: c1) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Classes IPC  ?

• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to a method for segmenting a digital image, for example to accurately segment cerebral vasculature on MRI-TOF images of a brain. The method first uses a model that imitates the perception of luminance contrasts by a human observer to accentuate a contrast between structures of interest, such as cerebral vasculature, and the image background. Then, the image is thresholded using an adaptive threshold. This enhanced segmentation method can be used to process digital images before launching further machine-implemented characterizations of the structures of interest, such as detecting and characterizing bifurcations of the cerebral vasculature for intra-cranial aneurysm prediction.

Classes IPC  ?

• G06T 5/00 - Amélioration ou restauration d'image
• G06T 7/11 - Découpage basé sur les zones
• G06T 7/136 - Découpage; Détection de bords impliquant un seuillage

Abrégé

6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.

Classes IPC  ?

• A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide
• A61P 11/06 - Antiasthmatiques

Abrégé

The present invention concerns a compound of following general formula (I): for use for treating cancer.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• C07D 487/04 - Systèmes condensés en ortho
• C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
• C07D 495/04 - Systèmes condensés en ortho
• C07D 513/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to a method for radioiodination or radioastatination of a biomolecule such as proteins and antibodies by reacting a biomolecule carrying a hetero(aryl) boronic acid group with a radioiodide or astatide salt, in the presence of a catalyst and a ligand, in a buffer solution, in order to obtain a radioiodo- or astatolabeled biomolecule. The method of the invention is thus a single step method easy to be implemented and efficient for both radioiodination and radioastatination of antibodies.

Classes IPC  ?

• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07F 5/02 - Composés du bore

Abrégé

Technics are known to use vessel bifurcations detection to obtain access to the detection of aneurysms. However, such technics suffer from a relatively poor accuracy. Therefore, the Applicants have developed a specific method for locating and characterizing bifurcations of a cerebral vascular tree based on a graph analysis of a three-dimensional skeleton of the tree. This enables to determine more accurately the vessel bifurcations. Such property can be used advantageously for several applications such as predicting the risk of developing an aneurysm, diagnosing an aneurysm, identifying a therapeutic target, identifying a biomarker or screening a compound.

Classes IPC  ?

• G06T 7/00 - Analyse d'image

Abrégé

The present invention concerns a compound having the following formula (I): 6)alkyl group, and R being preferably a group having the following formula (II): for use for the treatment of cancers, such as metastatic cancers.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons

Abrégé

+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).

Classes IPC  ?

• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

The present invention concerns a compound having the following formula (I): wherein:- A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, andR being preferably a group having the following formula (II): - X is in particular chosen from the group consisting of: -SO2-N(R'b)-, R'bbeing H or a (C1-C6)alkyl group, -N(R”b)-SO2-, R”b being H or a (C1-C6)alkyl group,-CO-NH-, and -NH-CO-,for use for the treatment of cancers, such as metastatic cancers.

Classes IPC  ?

• C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• C07C 311/44 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons ayant des atomes de soufre de groupes sulfonamide et des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons

Abrégé

The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in particular chosen from the group consisting of: -SO2-N(R'b)-, R'b being H or a (C1-C6)alkyl group, -N(R"b)-SO2-, R"b being H or a (C1-C6)alkyl group, -CO-NH-, and -NH-CO-, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.

Classes IPC  ?

• C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 311/44 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons ayant des atomes de soufre de groupes sulfonamide et des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide
• A61P 11/06 - Antiasthmatiques

Abrégé

aa162bb16b2b166)alkyl group, -CO-NH-, and -NH-CO-, for use for the treatment of cancers, such as metastatic cancers.

Classes IPC  ?

• C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 311/44 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons ayant des atomes de soufre de groupes sulfonamide et des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide

Abrégé

The present invention concerns a compound having the following formula (VII): wherein: - X' is -S- or -CH2-; - p is an integer comprised between 1 and 3; - Rs is a (Ci-C6)alkyl group; and - R4 groups, identical or different, are chosen from (Ci-C6)alkyl groups for use for the treatment of pathologies characterized by bronchoconstriction.

Classes IPC  ?

• C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide
• A61P 11/06 - Antiasthmatiques
• C07C 311/44 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons ayant des atomes de soufre de groupes sulfonamide et des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons

Abrégé

The present invention relates to a compound of the following general formula (I): (I) in which: - either R represents a group Ri and R' represents a group -ArCy1, or R represents a group -ArCy1 and R' represents a group R1; R1 especially representing H or a (C1-C6)alkyl group; A1 representing an -NH- radical or an -NH-CH2- radical; Cy1 especially representing a phenyl group, - A represents a (hetero)aromatic fused ring comprising from 5 to 7 atoms, for use thereof for treating cancers.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 35/00 - Agents anticancéreux
• C07D 239/42 - Un atome d'azote

Abrégé

The present invention relates to a compound of the following general formula (I): (I) in which: - either R represents a group Ri and R' represents a group -ArCy1, or R represents a group -ArCy1 and R' represents a group R1; R1 especially representing H or a (C1-C6)alkyl group; A1 representing an -NH- radical or an -NH-CH2- radical; Cy1 especially representing a phenyl group, - A represents a (hetero)aromatic fused ring comprising from 5 to 7 atoms, for use thereof for treating cancers.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• C07D 239/42 - Un atome d'azote
• A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9+ B cells in a blood sample of the subject, b) comparing the level of CD9+ B cells measured at step a) with one or more reference values of the level of CD9+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus

Abrégé

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Classes IPC  ?

• C12N 7/02 - Isolement ou purification
• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• B01D 15/36 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p.ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions

Abrégé

The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

Classes IPC  ?

• A61L 27/38 - Cellules animales
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
• A61K 35/39 - Appareil digestif Îlots de Langerhans
• A61K 47/38 - Cellulose; Ses dérivés
• A61K 9/16 - Agglomérés; Granulés; Microbilles
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The invention relates to a method for the cryopreservation of at least one sample of tumour-infiltrating lymphocytes, comprising the following steps: i) the in vitro culture of tumour-infiltrating lymphocytes using a collection of samples of in-transit skin nodules, ganglion or metastasis, from a patient with a stage III or IV melanoma, said step comprising the emergence of the tumour-infiltrating lymphocytes contained in the sample of in-transit skin nodules, ganglion or metastasis, followed by the stimulation of the tumour-infiltrating lymphocytes resulting from the emergence step, and, subsequently, the amplification of the stimulated tumour infiltrating lymphocytes; ii) the mixing of at least one sample obtained in step (i) with a composition comprising, in a physiologically acceptable medium, a) human albumin serum, b) at least one saccharide, and c) at least two ingredients selected from among DMSO, L-cysteine, coenzyme Q10 and C3-C5 alkanediols; and subsequently iii) the freezing of the mixture obtained in step (ii).

Classes IPC  ?

• C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
• A01N 1/02 - Conservation de parties vivantes

Abrégé

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion- exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Classes IPC  ?

• C12N 15/864 - Vecteurs parvoviraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
• C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 7/02 - Isolement ou purification
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 15/55 - Hydrolases (3)

Abrégé

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: cl) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Classes IPC  ?

• C12N 15/864 - Vecteurs parvoviraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 7/02 - Isolement ou purification
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 15/55 - Hydrolases (3)

Abrégé

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: cl) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Classes IPC  ?

• C12N 7/02 - Isolement ou purification
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Abrégé

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion- exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Classes IPC  ?

• C12N 7/02 - Isolement ou purification
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Abrégé

The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.

Classes IPC  ?

• C07K 14/54 - Interleukines (IL)
• C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
• C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.

Classes IPC  ?

• C07K 14/54 - Interleukines (IL)
• C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
• C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention concerns a method for the in vitro diagnosis of a graft tolerant or non-tolerant phenotype, comprising determining from a grafted subject biological sample an expression profile comprising the 20 following genes: TCL1A, MZB1, CD22, BLK, MS4A1, CD79B, BLNK, FCRL2, IRF4, ID3, AKR1C3, HINT1, RFC4, ANXA2R, CD40, FCER2, CTLA4, AKIRIN2, EPS15 and PLBD1; comparing the obtained expression profile with at least one reference expression profile, and determining the graft tolerant or graft non-tolerant phenotype from said comparison.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

Classes IPC  ?

• A61K 35/36 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées Épiderme; Cellules épithéliales; Kératinocytes; Cellules de Langerhans; Cellules ectodermiques
• A61L 15/32 - Protéines, polypeptides; Leurs produits de dégradation ou leurs dérivés, p.ex. albumine, collagène, fibrine, gélatine
• A61L 15/40 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des ingrédients de constitution indéterminée ou leurs produits de réaction
• A61K 35/33 - Fibroblastes
• A61L 15/44 - Médicaments
• A61K 35/54 - Ovaires; Ovules fécondés; Ovules; Embryons; Cellules fœtales; Cellules germinales

Abrégé

The present invention relates to a method of predicting delayed graft function (DGF) after kidney transplantation in patient, said method comprising a step of calculating a score (DGFS) based on the following variables: induction therapy, Cold ischemia time (CIT), donor creatinin levels, donor age, and patient BMI. Methods for assessing the need for a DGF therapy after kidney transplantation are disclosed. A processing system including a computation unit and an input interface, characterized in that said system includes means for implementing the method for determining the risk of DGF is also provided.

Classes IPC  ?

• G01N 33/70 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir la créatine ou la créatinine
• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)

Abrégé

The invention relates to methods comprising a step consisting of determining the proportion and/or the level of T regulatory lymphocytes with a CD4+ CD8ααlow Foxp3neg phenotype specific for Faecalibacterium prausnitzii for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing, an inflammatory bowel disease in a patient. The invention also concerns the treatment of an inflammatory bowel disease. The invention further relates to the kits that are useful in the above methods for diagnosing / prognosing an inflammatory bowel disease, and in the treatment of an inflammatory bowel disease. In a particular embodiment, the inflammatory bowel disease is the Crohn's disease.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.

Classes IPC  ?

• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
• A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget de l'ostéoporose
• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

Abrégé

The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1 :1 or 7 :3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

Classes IPC  ?

• A61K 35/36 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées Épiderme; Cellules épithéliales; Kératinocytes; Cellules de Langerhans; Cellules ectodermiques
• A61K 35/54 - Ovaires; Ovules fécondés; Ovules; Embryons; Cellules fœtales; Cellules germinales
• A61L 15/40 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des ingrédients de constitution indéterminée ou leurs produits de réaction
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1 :1 or 7 :3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

Classes IPC  ?

• A61K 35/36 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées Épiderme; Cellules épithéliales; Kératinocytes; Cellules de Langerhans; Cellules ectodermiques
• A61K 35/54 - Ovaires; Ovules fécondés; Ovules; Embryons; Cellules fœtales; Cellules germinales
• A61L 15/40 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des ingrédients de constitution indéterminée ou leurs produits de réaction
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Classes IPC  ?

• A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
• A61K 47/38 - Cellulose; Ses dérivés
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
• C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• A61K 35/34 - Muscles; Cellules musculaires lisses; Cœur; Cellules souches cardiaques; Myoblastes; Myocytes; Cardiomyocytes
• A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées

Abrégé

The present invention concerns materials and methods for characterizing monoclonal immunoglobulin specificity of a Monoclonal Gammopathy of Undetermined Significance (MGUS) or Myeloma patients using a protein microarray comprising (a) a substrate, (b) antigens immobilized on the substrate, said antigens being selected from a defined group consisting of infectious agent antigens and/or self-antigens. In particular said protein microarray may be used to improve diagnosis, for the prognosis of myeloma or MGUS, for preventing transformation of MGUS toward myeloma, for adapting treatment of MGUS and myeloma or for monitoring the response to therapy of MGUS and myeloma patients.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• C40B 40/00 - Bibliothèques en soi, p.ex. matrices, mélanges
• G01N 33/576 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour l'hépatite

Abrégé

The present invention relates to a method for determining whether a cytomegalovirus infection in a transplanted patient is susceptible to induce allograft rejection comprising detecting the presence of at least one HLA-E-restricted CD8 αβ T cell population displaying reactivity against peptides derived from the leader sequences of both HCMV-UL40 protein and allogeneic classical HLA-I molecules in a blood sample of the patient, wherein the presence of said populations indicated that the cytomegalovirus infection in the transplant patient is susceptible to induce allograft rejection.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus

Abrégé

The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.

Classes IPC  ?

• C07F 15/00 - Composés contenant des éléments des groupes 8, 9, 10 ou 18 de la classification périodique
• A61K 31/24 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.

Classes IPC  ?

• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées

Abrégé

The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.

Classes IPC  ?

• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette

Abrégé

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
• C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

The present invention relates to an in vitro method for diagnosing the infectious state of an individual on the basis of a sample of white corpuscles arising from a biological specimen taken from an organ potentially infected by a pathogenic micro-organism of said individual, comprising at least the following two steps: i) measuring the mean cellular intensity of the autofluorescence of said sample, and ii) comparing the intensity measured in step i) with a control value, so as to determine the infectious state of said individual. The diagnostic method of the invention uses a routine optical material making it possible to work in wavelength regions which are compatible with the cellular autofluorescence, and thus constitutes a rapid, reliable and inexpensive aid for the diagnosis or monitoring of an infection in an individual.

Classes IPC  ?

• G01N 21/64 - Fluorescence; Phosphorescence

Abrégé

The present invention relates to an in vitro method for diagnosing the infectious state of an individual on the basis of a sample of white corpuscles arising from a biological specimen taken from an organ potentially infected by a pathogenic micro-organism of said individual, comprising at least the following two steps: i) measuring the mean cellular intensity of the autofluorescence of said sample, and ii) comparing the intensity measured in step i) with a control value, so as to determine the infectious state of said individual. The diagnostic method of the invention uses a routine optical material making it possible to work in wavelength regions which are compatible with the cellular autofluorescence, and thus constitutes a rapid, reliable and inexpensive aid for the diagnosis or monitoring of an infection in an individual.

Classes IPC  ?

• G01N 15/05 - Recherche de la sédimentation des suspensions de particules dans du sang

Abrégé

Bone regeneration membrane (1) comprising: a dense layer (2) made of resorbable polymer, said dense layer (2) having first and second opposite surfaces and being adapted to form a barrier to cells and soft tissues, a nanofibrillar layer (3) made of resorbable polymer and attached to the first surface of the dense layer (2), said nanofibrillar layer comprising fibers having a diameter of nanometer size, said fibers being interlaced so as to present an average pore size greater than 10 μm to allow cell permeability and bone tissue regeneration, the nanofibrillar layer (3) having a permeability κ between 0.4 * 10-9 m2 and 11 * 10-9 m2, preferably between 1 * 10-9 m2 and 4 * 10-9 m2, in particular substantially of 2 * 10-9 m2..

Classes IPC  ?

• A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques

Abrégé

The present invention relates to a method for detecting the presence or the absence, and optionally quantifying and/or isolating, antigen-specific peripheral blood mononuclear cells. This method, which involves flow cytometry, is based on the use of a fluorescently- labeled antibody specifically recognizing peripheral blood mononuclear cells, and of fluorescently-labeled beads coated with at least one antigen that is specifically recognized by antigen-specific peripheral blood mononuclear cells. The method according to the invention is for example useful for diagnosing immune disorders such as transplant rejections and autoimmune disorders.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus

Abrégé

The invention relates to a method of in-vitro evaluation of the physiological state of a gastric mucous membrane on the basis of exfoliated cells isolated from a biological fluid of a human or nonhuman animal individual, according to which said cells are subjected to a set of antibodies able to interact with protein markers from among at least one autophagia marker and at least one clock marker. Advantageously, anti-SURVIVIN antibodies and/or anti-LC3 antibodies are used as autophagia markers. Likewise, anti-PERIOD1 antibodies and/or anti-CLOCK antibodies are used as clock markers. The invention also relates to a kit comprising a set of antibodies capable of being used for said method.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a compound having formula (I): wherein: - X is in particular 125I Or 211At; - R1 and R'1 are independently from each other chosen preferably from the group consisting of electron-withdrawing groups and alkyl groups; - R2 is chosen from the group consisting of : H, alkyl groups, functional groups being able to bind a vector, and functional groups having targeting properties which make the compound of the invention a vector itself; - Z is a heteroatom, - R5, R8 and R9 are preferably H; - Y is preferably an electron withdrawing group.

Classes IPC  ?

• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques

Abrégé

The invention concerns: - a silylated biomolecule having the following formula (I): - the process for the preparation of a silylated biomolecule of formula (I), - the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, - a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), - the hydrogel obtainable by said process, - said hydrogel as a biological tissue substitute, - a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, - said composition for the release of active principle.

Classes IPC  ?

• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si

Abrégé

The present invention relates to a pharmaceutical composition that includes at least one agonist of at least one receptor of the ToII type (TLR) selected from TLR 4 and 9, and to be used in the prophylactic treatment of septic complications of post-traumatic systemic immune depression in a patient suffering from one or more severe traumas and hospitalized, in particular in a hospital resuscitation ward. Said TLR 4 agonist is preferably the monophosphoryl lipid A (MPLA) or the 3-0 deacylated monophosphoryl lipid A (3D-MPLA), and said TLR 9 agonist is a CpG oligodeoxynucleotide (CpG ODN).

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques

Abrégé

The invention relates to a method for determining a risk of permanent rejection of a graft after being transplanted to a recipient, said method being characterized in that it includes the following steps: (a) entering physiological/clinical characteristics of the recipient and the donor into a computation unit by means of an input interface, said characteristics including the gender of the recipient, the creatinine level of the graft donor when sampled, the age of the recipient at the time of the transplant, -the number of renal transplants previously received by the recipient, - a creatinine level of the recipient measured twice at at least one predetermined point in time after the transplant, a proteinuria level of the recipient measured at a predetermined point in time after the transplant, and the existence of an episode of permanent rejection of the transplant during the first year of the transplant; (b) determining the parameters on the basis of said characteristics; (c) combining said parameters so as to obtain a risk score of permanent rejection of the graft; and (d) analyzing said risk score so as to determine a risk of permanent rejection of a graft.

Classes IPC  ?

• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)

Abrégé

The invention relates to 5'-adenosine monophosphate-activated protein kinase (AMPK) activators such as biguanide derivatives and 5-aminoimidazole-4-carboxamide riboside (AICAR) or derivatives thereof for use in preventing and/or treating pulmonary hypertension.

Classes IPC  ?

• A61K 31/155 - Amidines (), p.ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides  contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61P 9/12 - Antihypertenseurs

Abrégé

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens.

Classes IPC  ?

• G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: - n and m denote, independently of one another, an integer ranging from 1 to 4, - X denotes an oxygen atom or an N-R3 group, - R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and - R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.

Classes IPC  ?

• C07F 9/38 - Acides phosphoniques (R—P(:O)(OH)2); Acides thiophosphoniques
• A61K 31/663 - Composés ayant plusieurs groupes acide du phosphore ou leurs esters, p.ex. acide clodronique, acide pamidronique
• A61P 3/14 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase des électrolytes de l'homéostase du calcium
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget de l'ostéoporose
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a method for preparing a hydroxy-bisphosphonic acid derivative or a salt thereof, from the corresponding carboxylic acid, comprising the following steps: - activation of the carboxylic acid function in the form of the boronate derivative thereof through the action of a borane, then - reaction with tris(trimethyl­silyl)phosphite, under Arbuzov conditions - treatment with an alcohol, chosen in particular from an aliphatic alcohol or trifluoromethanol, and - separation of the hydroxy-bisphosphonic acid derivative formed, from the reaction medium.

Classes IPC  ?

• C07F 9/38 - Acides phosphoniques (R—P(:O)(OH)2); Acides thiophosphoniques

Abrégé

The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: - n and m denote, independently of one another, an integer ranging from 1 to 4, - X denotes an oxygen atom or an N-R3 group, - R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and - R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.

Classes IPC  ?

• C07F 9/38 - Acides phosphoniques (R—P(:O)(OH)2); Acides thiophosphoniques
• A61K 31/663 - Composés ayant plusieurs groupes acide du phosphore ou leurs esters, p.ex. acide clodronique, acide pamidronique
• A61P 35/00 - Agents anticancéreux
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget de l'ostéoporose
• A61P 3/14 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase des électrolytes de l'homéostase du calcium